


AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4278

TITLE: Development of Ligand-Transformed Alpha-Fetoprotein  
for Use Against Breast Cancer in Humans

PRINCIPAL INVESTIGATOR: James A. Bennett, Ph.D.

CONTRACTING ORGANIZATION: Albany Medical College  
Albany, New York 12208



REPORT DATE: 1 July 1995

TYPE OF REPORT: Annual

19951003 044

PREPARED FOR:

U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

DTIC QUALITY INSPECTED 5

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 1 July 1995	3. REPORT TYPE AND DATES COVERED Annual 1 Jul 94 - 30 Jun 95		
4. TITLE AND SUBTITLE Development of Ligand-Transformed Alpha-Fetoprotein for Use Against Breast Cancer in Humans			5. FUNDING NUMBERS DAMD17-94-J-4278	
6. AUTHOR(S) James A. Bennett, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Albany Medical College Albany, New York 12208			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Human alpha-fetoprotein (hAFP) upon incubation with sex steroid hormones is chemically converted into an inhibitor of estrogen-dependent breast cancer growth. This document describes the progress which was made during the first year of a research grant which was designed to develop the active form of hAFP as a treatment for breast cancer and establish markers which both predict and monitor breast cancer responsiveness to this form of AFP. The full-length molecule of hAFP was produced from the recombinant human gene placed in an <i>E. coli</i> expression system. This product was found to be convertible to an active form which inhibited estrogen-dependent growth of human breast cancer grown as a monolayer in culture and as a xenograft in mice. The third domain of hAFP was produced from a recombinant, truncated gene placed in a baculovirus expression system. This product was activable and retained all of the activity found in the full-length molecule. A mammalian cell culture system was developed which produced hAFP already in its active form. This product was also quite effective in retarding breast cancer growth. Further development of these products is underway, as is predicting and monitoring breast cancer responsiveness to the active form of AFP.				
14. SUBJECT TERMS alpha-fetoprotein, growth regulation, MCF-7 breast cancer			15. NUMBER OF PAGES 22	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

**Block 1.** Agency Use Only (Leave blank).

**Block 2.** Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3.** Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4.** Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5.** Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6.** Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7.** Performing Organization Name(s) and Address(es). Self-explanatory.

**Block 8.** Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9.** Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

**Block 10.** Sponsoring/Monitoring Agency Report Number. (If known)

**Block 11.** Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a.** Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b.** Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13.** Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14.** Subject Terms. Keywords or phrases identifying major subjects in the report.

**Block 15.** Number of Pages. Enter the total number of pages.

**Block 16.** Price Code. Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19.** Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20.** Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

*JaB* In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

*JaB* In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

*JaB* In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

*James A. Bennett* 7-24-95  
PI - Signature Date

## Table of Contents

	<u>Page</u>
Front Cover .....	1
SF 298 Form .....	2
Foreword .....	3
Table of Contents .....	4
Introduction .....	5
Body .....	12
Conclusions .....	20
References .....	21
Bibliography of Publications .....	22
Personnel Receiving Pay .....	22

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification .....	
By .....	
Distribution /	
Availability Codes	
Dist	Avail and / or Special
A-1	

## Introduction

### (a) Nature of the problem

Epidemiological and literature studies strongly suggest that alpha-fetoprotein (AFP) is the endogenous factor in pregnancy which confers on parous women their significant reduction in risk of breast cancer. Our laboratory studies support this connection by demonstrating that natural human AFP undergoes a conformational change in the presence of ligands that have receptors in the steroid/thyroid hormone receptor superfamily; and this transformed product (*t*AFP) stops the growth of human breast cancer growing in culture and as xenografts. Our technical objective is to develop *t*AFP into a therapeutic agent for breast cancer. Recombinant (*r*) AFP has been produced for this purpose.

### (b) Background

*Epidemiology and literature studies showing the relationship between AFP and breast cancer.* An experiment of nature suggests that alpha-fetoprotein (AFP) is the factor in pregnancy which confers on parous women their significant reduction in risk of breast cancer. As shown in Table 1a, AFP is elevated in maternal serum during pregnancy. Furthermore, there are factors in pregnancy such as maternal race, weight, hypertension, consumption of alcohol, number of fetuses *in utero*, and neural tube defect in the fetus where maternal serum AFP (MSAFP) is substantially altered from normal pregnancy levels. In studying the literature, we have found the consistent and striking correlation that in those pregnancy conditions associated with an elevated level of MSAFP, there was a significant reduction in the lifetime risk to the mother of acquiring breast cancer (1). Conversely, in pregnancy conditions characterized by low MSAFP (alcohol), subsequent breast cancer risk was elevated (Table 1a). We carried out epidemiologic studies analyzing retrospective data that extend and confirm the correlation between MSAFP levels and breast cancer risk (Table 1b). Recently Ekbom et al. (2) have published an epidemiological study which suggests that, at least in the case of hypertension during pregnancy, the reduction of breast cancer risk is also passed on to the fetus. He is in agreement with our speculation that it is AFP in the fetal and maternal circulation that protects the offspring as well as the mother against later development of breast cancer.

Table 1  
**Association of High Maternal Serum AFP with Decreased Breast Cancer Risk**

Maternal Conditions		Maternal Serum AFP Concentration	Maternal Lifetime Breast Cancer Risk
1	2		
<b>1a</b>			
Pregnant	vs. Non-pregnant	1 > 2 (3)*	1 < 2 (4)
Pregnant, black	vs. Pregnant, white	1 > 2 (5)	1 < 2 (6)
Pregnant, lean	vs. Pregnant, obese	1 > 2 (5)	1 < 2 (7)
Pregnant, consuming no alcohol	vs. Pregnant, consuming alcohol	1 > 2 (8)	1 < 2 (9)
<b>1b</b>			
Pregnant, hypertensive	vs. Pregnant, normotensive	1 > 2 (10)	1 < 2 (11)
Pregnant, with multiple fetuses	vs. Pregnant, with a single fetus	1 > 2 (12)	1 < 2 (13)
Pregnant, fetus with neural tube defect	vs. Pregnant, fetus no neural tube defect	1 > 2 (14)	1 < 2 (15)

\*The numbers in the brackets are the reference sources for the data.

*Growth regulation of hormone-dependent normal tissues by transformed AFP.* We have carried out laboratory studies which support the above theory derived from epidemiological studies. AFP was isolated from human cord sera (16). Incubation of AFP with estrogen for one hour at room temperature generated a product which inhibited growth of estrogen-stimulated mouse uterus (Table 2). AFP alone did not inhibit growth.

Table 2  
**Inhibition of Estradiol (E<sub>2</sub>)-Stimulated Mouse Uterine Growth<sup>a</sup>**  
**by Transformed Human AFP**

Injectant 1	<i>1 hr</i> →	Injectant 2	Mean Uterine <sup>e</sup> Weight ± S.E. (mg/g body wt)	Growth <sup>f</sup> Inhibition %
Saline		Saline	0.98 ± 0.04	
Saline		E <sub>2</sub> <sup>d</sup>	1.61 ± 0.06	
E <sub>2</sub> <sup>d</sup>		E <sub>2</sub>	1.63 ± 0.06	
AFP/Sal <sup>b</sup>		E <sub>2</sub>	1.60 ± 0.05	2
AFP/E <sub>2</sub> <sup>c</sup>		E <sub>2</sub>	1.43 ± 0.04 <sup>g</sup>	31

<sup>a</sup> Immature (15-18 day old) female Nya:NYLAR mice were used for uterine growth experiments.

<sup>b</sup> 5 µg/ml AFP was added to an equal volume of saline and incubated at room temperature for 1 hr. 0.1 ml of this incubation mixture was injected i.p. into each mouse.

<sup>c</sup> 5 µg/ml AFP was added to an equal volume of 10 µg/ml E<sub>2</sub> and incubated at room temperature for 1 hr. 0.1 ml of this incubation mixture was injected i.p. into each mouse.


<sup>d</sup> 0.5 µg E<sub>2</sub> in 0.1 ml was injected i.p. to stimulate uterine growth.

<sup>e</sup> Twenty-two hours following administration of injectant 2, uteri were excised and uterine wet weights were determined. There were a minimum of 5 replicate mice per group.

<sup>f</sup> Percent growth inhibition was calculated as the AFP-induced reduction in E<sub>2</sub>-stimulated uterine growth divided by the full E<sub>2</sub>-stimulated increase in uterine growth multiplied by 100%.

<sup>g</sup> Significant inhibition, *p* < 0.05; Wilcoxon Sum of Ranks Test.


We have designated this product transformed AFP (*t*AFP), since all of the biological activity was contained in the large molecular weight (>10 kDa) fraction of the reaction mixture. A chemical reaction takes place during the incubation as evidenced by the time-dependent appearance of a difference spectrum in the ultraviolet region with λ max at 290 nm (17). The uniqueness of the reaction is demonstrated by the fact that incubation of AFP's closest homolog, fetal albumin, with estradiol under identical conditions did not result in a biologically active product (18) and did not produce a difference spectrum (17). Also, antibody to human AFP completely blocked generation of antiestrogenic activity (16). A molar excess of ligand to AFP was required to generate both the difference spectrum and the biological activity. As shown in Figure 1, ligands in addition to estrogens convert AFP to its growth-inhibitory form. These ligands have in common the fact that they all have receptors which belong to the steroid/thyroid hormone receptor superfamily (19). Hormones and vitamins that do not belong to this superfamily do not transform AFP. This suggests that the mechanism of action of *t*AFP is an interference with common biochemical pathways utilized by the receptors in this superfamily.



**Fig. 1. Ligands used to activate AFP.** The experimental design was similar to that described in Table 2, except that ligands other than estradiol were used to activate AFP. The control for ligand-activated AFP was ligand alone in the first injection followed by E<sub>2</sub> in the second injection. In no case were these controls inhibitory.


***Growth inhibition of hormone-dependent breast cancer by tAFP.*** The estrogen-dependent MTW9A rat mammary tumor growing in syngeneic Wistar-Furth rats regressed during treatment with E<sub>2</sub>-transformed AFP. Upon cessation of treatment, tumors resumed growth. Albumin treated with E<sub>2</sub> under similar reaction conditions did not inhibit tumor growth (Fig. 2) (20).

#### MTW9A Rat Tumor



**Fig. 2. Effect of AFP/E<sub>2</sub> on growth of the estrogen-dependent MTW9A rat mammary tumor in a syngeneic rat.** Estrogen dependence of tumor growth was verified by removal (↓) and reinsertion (↑) of Silastic E<sub>2</sub> implants. Injections of AFP/E<sub>2</sub> (0.8 μg rat AFP/0.2 μg E<sub>2</sub>, preincubated for 60 min) were given i.p. twice daily for 5 days in a volume of 0.1 ml. When similar quantities of albumin/E<sub>2</sub> were given to the same rat 20 days later, tumor growth was not affected.

## MCF-7



**Fig. 3. Inhibition of MCF-7 breast cancer xenografts by *t*AFP.**

\* AFP/E<sub>2</sub> = *t*AFP

\*\* Si/E<sub>2</sub> = 1 cm Silastic tubing filled with solid estradiol, sealed at both ends and implanted subcutaneously

Similarly, *t*AFP stopped the growth of estrogen-dependent human MCF-7 breast cancer (Fig. 3). These tumors were growing as xenografts under the kidney capsule of immunosuppressed, estrogenized mice. Daily treatment from day 7 to day 14 with E<sub>2</sub>-transformed human AFP substantially inhibited tumor growth, resulting in no increase in tumor volume during treatment. In contrast, tumor volume increased by 55% during treatment with untransformed AFP. Tamoxifen, which is now standard treatment for estrogen-receptor-positive breast cancer, also substantially inhibited growth of these tumor xenografts. Its potency was similar to that of *t*AFP.

*Recombinant AFP has biological activity similar to that of natural AFP.* It became clear to us that the supply of natural AFP would not be sufficient for clinical trials. Therefore, we looked for a source of recombinant AFP that could be tested for biological activity in our bioassays. Dr. K. Muira (KRI International, Japan) supplied us with Domain I of human AFP expressed in *E. coli*, and Dr. Shinzo Nishi (Hokkaido University, Sapporo, Japan) supplied us with full-length human AFP expressed in yeast. As shown in Table 4, Domain I of human AFP was not activable to antiestrogenic activity. However, full-length human AFP expressed in yeast had substantial antiuterotrophic activity. Unfortunately, Dr. Nishi encountered production problems with the recombinant human AFP expressed in yeast and was not able to supply us with additional AFP. Recently we established a collaboration with Dr. Robert Murgita (McGill University, Montreal, Canada). He has been able to supply us with recombinant human AFP-full length molecule, expressed in an *E. coli* system and in the baculovirus system. In the baculovirus system, AFP is glycosylated, whereas in the *E. coli* system, it is not. As shown in Table 3, all of the full-length molecules could be activated to antiestrogenic activity.

Table 3  
**Inhibition of E<sub>2</sub>-Stimulated Mouse Uterine Growth  
 by Different Sources of Transformed Recombinant AFP**

<i>AFP Source</i>	<i>% Inhibition of E<sub>2</sub>-Stimulated Mouse Uterine Growth<sup>4</sup></i>
Human Cord Sera.....	31
Yeast; Recombinant Human, Full-length <sup>1</sup> .....	45
<i>E. coli</i> ; Recombinant Human, Full-length <sup>2</sup> .....	28
<i>E. coli</i> ; Recombinant Human, Domain I <sup>3</sup> .....	0
Baculovirus/Sf9 cells; Recombinant Human, Full-length <sup>2</sup> .....	22
Mouse Amniotic Fluid.....	42
<i>E. coli</i> ; Recombinant Mouse, Full-length <sup>2</sup> .....	31
Baculovirus/Sf9 cells; Recombinant Mouse <sup>2</sup> .....	26

<sup>1</sup>Obtained from Dr. Shinzo Nishi, Hokkaido University, Sapporo, Japan

<sup>2</sup>Obtained from Dr. Robert Murgita, McGill University, Montreal, Quebec, Canada

<sup>3</sup>Obtained from Dr. K. Miura, KRI International, Tokyo, Japan

<sup>4</sup>AFPs at doses of 1 µg, 0.5 µg or 0.25 µg, either transformed by 0.5 µg E<sub>2</sub> or in its native state, were tested in the mouse uterus bioassay. 0.25 µg was an optimal inhibitory dose for *t hAFP*; 1.0 µg was optimal for *t mAFP*. Untransformed or native AFP resulted in values of less than 8% inhibition.

Support from this grant will enable us to continue evaluation of recombinant human AFP as an oncostatic agent against breast cancer cells growing in culture and as xenografts *in vivo*. Dr. Murgita has agreed to supply us with an amount of recombinant human AFP that will be more than sufficient to complete the aims of this study. Moreover, he is highly committed to the development of AFP all the way to clinical trials for both immunoregulatory diseases, which is his interest, and for breast cancer and perhaps other endocrine cancers, which is our interest. However, to be absolutely sure that the supply of recombinant AFP does not become limiting, as was the case in our collaboration with Dr. Nishi, my collaborators at Albany Medical College have begun to produce recombinant human AFP in the baculovirus expression system. The fact that recombinant AFP possesses this antioncotic property indicates that we have a means through which AFP can be produced in sufficient quantity for clinical trial.

*Physiological relevance of tAFP.* Although the research proposed in this document is focused on the pharmacological application of *tAFP* for the treatment of breast cancer, the epidemiological and laboratory studies described above suggest a physiological relevance for *tAFP*. AFP is secreted primarily by the fetal liver, is a major protein component of fetal plasma and crosses the placenta into the maternal circulation (21). In pregnant women, estrogen, progestins and androgens are produced primarily by the placenta and readily cross into the fetal circulation (22). Thus the conditions exist *in utero* for reaction of AFP with sex steroid hormones to produce *tAFP* in the fetal plasma. The physiological role of AFP, and especially *tAFP*, may be to act as a rudimentary servo mechanism which desensitizes endocrine tissues to inappropriately high levels of hormones which occur during gestation, since the fetus develops in the presence of a large concentration of maternal and placental hormones, has receptors for these hormones, but early on does not have the sophisticated control mechanisms of late fetal or adult life to regulate

the production of and response to these hormones. A "side effect" would occur when *t*AFP crossed the placenta into the maternal circulation where it would extinguish microscopic premalignant and/or cancerous foci in the breast that later on in life would be promoted to clinically detectable breast cancers. Such a "side effect" would explain the epidemiological data described in Table 1.

### **(c) Hypothesis/Purpose**

Our working hypothesis is that AFP interacts with ligands in the steroid/thyroid hormone receptor superfamily and undergoes a conformational change, producing a growth-regulatory molecule which stops the growth of hormone-receptor-positive breast cancer. The studies proposed in this application have as their purpose the generation of requisite preclinical data which will underpin the clinical application of ligand-transformed AFP (*t*AFP) in patients with breast cancer. The specific aims are:

### **(d) Specific Aims/Technical Objectives**

1. Transform recombinant AFP to its active state in a way that both maximizes its antitumor activity and sustains its lack of host toxicity. This will entail selecting the appropriate activating ligand. For activation it seems wise to avoid ligands that themselves could be trophic for the breast, such as estrogens and progestins. Therefore the focus will be on vitamin A analogs and vitamin D analogs, since (a) the parent compounds in these families are as effective as estradiol in converting AFP to its active form (Fig. 1); (b) both of these ligand families when used alone decrease proliferation and increase differentiation of certain cancers, including breast cancers, and are themselves beneficial; and (c) there is extensive clinical experience with these agents.
2. Identify cellular markers that predict tumor responsiveness to *t*AFP. This will entail evaluating characteristics in the tumor, such as tissue type, level of sex steroid hormone receptors, level of AFP receptor and level of IGF receptor, and correlating these tumor markers with the growth-inhibitory response to *t*AFP.
3. Develop non-invasive tests that monitor biological activity of *t*AFP in the host. A decrease in serum levels of IGF<sub>1</sub>, an increase in circulating FSH and LH, and a decrease in serum levels of breast-cancer-associated antigen (CA 15-3), would all be indicative of *in vivo* biological activity of *t*AFP and are rational choices to use as intermediate markers of tumor response to *t*AFP.
4. Characterize the cell cycle changes and type of growth arrest induced by *t*AFP. In this aim we will determine whether *t*AFP causes cells to accumulate in a particular phase of the cell cycle, whether cell death accompanies growth arrest during long-term treatment with *t*AFP, whether cell death is via apoptosis, necrosis or a combination of both, and whether the information garnered from these experiments can be used to synergistically combine *t*AFP with other agents.

Other aims that are important but are not a part of this proposal are study of the mechanism of action of *t*AFP at the molecular level in the tumor target cell, identification of the active site on the *t*AFP molecule, and genetic engineering and/or peptide synthesis of a smaller molecule that bears the active site and has antitumor activity. These studies are being carried out by my colleagues at Albany Medical College and at the Wadsworth Center for Laboratories and

Research of the New York State Department of Health, and support for these studies is being requested in separate grant proposals. We have assembled a team of intramural and extramural scientists with a broad spectrum of essential skills to develop, understand and apply *t*AFP as a new agent for the prevention and treatment of breast cancer. To the best of our knowledge, we are the only group in the U.S. pursuing this unique property of AFP.

## Body

### a. Methods and Results Obtained

Three sources of AFP were evaluated for their ability to be transformed into inhibitors of estrogen-stimulated human breast cancer growth. The three sources were 1] recombinant human AFP produced in an *E. coli* expression system (ErhAFP) by our collaborators at McGill University, 2] recombinant human AFP (Domain III) produced in a baculovirus expression system (BrhAFP) by coinvestigators on the grant who are at Albany Medical College, and 3] natural human AFP (NhAFP) secreted from a human hepatoma carried in culture at Albany Medical College.

*Results with ErhAFP.* Several batches of ErhAFP were prepared and tested for antiestrogenic activity. Our primary screen was inhibition of estrogen-stimulated mouse uterine growth described earlier in Table 2, because of its quick turn-around time, low cost and in vivo nature. As shown in Table 4, only batch 18 provided reliable antiestrogenic activity.


Table 4  
Effect of Different Batches of E<sub>2</sub>-Transformed ErhAFP  
on Estrogen-Stimulated Mouse Uterine Growth

Batch of ErhAFP	% Inhibition of E <sub>2</sub> -Stimulated Mouse Uterine Growth (replicate experiments) <sup>a</sup>
14	7
15	13
16	28,* 20
17	0
18	38,* 33,* 33,* 39* <sup>b</sup>
19	39,* 28

<sup>a</sup> Inhibition of E<sub>2</sub>-stimulated mouse uterine growth was established with all the controls described in Table 2 for each experiment.

<sup>b</sup> Significant inhibition,  $p < 0.05$ , Wilcoxon Sum of Ranks Test.

The other batches were just as pure as 18 and by all criteria (molecular weight, reactivity with anti-AFP and sequencing of N-terminal amino acids) identified as AFP. The basis for their lack of activity is not clear. One possibility is that in isolating the AFP from *E. coli*, the material may have been exposed for too long a time to harsh chemical conditions required to lyse the *E. coli* and break down the inclusion bodies where the AFP was stored. Of all the batches, 18 was exposed to these conditions for the least amount of time.




**Fig. 4. Inhibition of growth of MCF-7 Breast cancer cells in culture by tErhAFP.**

Batch 18 was evaluated for its ability to inhibit estrogen-stimulated growth of human MCF-7 breast cancer cells into postconfluent foci. As shown in Figure 4, transformed ErhAFP significantly inhibited the growth of human MCF-7 breast cancer cells in culture, whereas untransformed AFP, albumin and albumin exposed to transforming conditions were without effect.

Erh AFP was then tested against MCF-7 human breast cancer growing as a xenograft under the kidney capsule of immune-deficient mice. Tumors were implanted and growth was established for 10 days prior to treatment.

As shown in Figure 5, the tumor was completely dependent on estrogen (Silastic subcutaneous implants containing estradiol, Si/E<sub>2</sub>) for growth. Treatment was carried out from day 10 to day 20 after implantation by daily i.p. administration of test agents. E<sub>2</sub>-transformed ErhAFP significantly inhibited tumor growth during the treatment interval. However, tumor growth resumed upon cessation of treatment. This was similar to the effect of tamoxifen, which was evaluated as a positive control in the same experiment. Untransformed AFP was without effect.



**Fig. 5. MCF-7 with tErhAFP (treatment interval days 10-20)**




Fig. 6. MCF-7 with  $\tau$ ErhAFP (treatment interval days 0-20)

In contrast, the estrogen-receptor-negative MDA-MB-231 human breast cancer was not dependent on estrogen for growth and was not inhibited by either transformed ErhAFP, untransformed ErhAFP, or tamoxifen (Figure 7). This suggests that the mechanism of action of transformed AFP is through the estrogen receptor. However, additional ER-positive and ER-negative human breast cancers need to be evaluated to establish this point.




Fig. 7. MDA-MB-231 with  $\tau$ ErhAFP (treatment interval days 10-20)

In the above experiments batch 18 Erh AFP was transformed by incubation with E<sub>2</sub> to an inhibitor of estrogen-stimulated growth. We had preliminary data that retinoids could also transform hAFP to an inhibitor of estrogen-dependent mouse uterine growth (23). Since retinoid-transformed AFP would be more appropriate than E<sub>2</sub>-transformed AFP for clinical use against breast cancer, experiments were carried out to evaluate the ability of retinoids to transform ErhAFP to an inhibitor of estrogen-dependent growth. Several concentrations of batch 18 ErhAFP were incubated with 5  $\mu$ g/ml 13-cis-retinoic acid (13cRA) for one hour at room

The impact of earlier and more prolonged treatment was assessed, and the results are shown in Figure 6. If treatment was initiated at the time of tumor implantation and continued daily for 20 days, significant growth inhibition was obtained. Inhibition was greater for the first 10 days of treatment compared to the second 10 days of treatment. Upon examination of tumors during survival laparotomy required for measurements of tumor size, there was no indication that neovascularization had been inhibited. In fact, gross as well as histological assessments were consistent with viable tumor in a state of cytostasis as a result of treatment.

temperature. As shown in Table 5, the reactant ratio of 2.5  $\mu\text{g/ml}$  AFP to 5  $\mu\text{g/ml}$  13cRA yielded a product with antiestrogenic activity similar to that obtained when  $\text{E}_2$  was used as the activating ligand. AFP alone and 13cRA alone had no effect on  $\text{E}_2$ -stimulated growth of mouse uterus.

Table 5  
Inhibition of  $\text{E}_2$ -Stimulated Mouse Uterine Growth  
by Retinoid-Transformed ErhAFP

Injectant 1	1 hr →	Injectant 2	Mean Uterine Weight $\pm$ SE (mg/g body wt)	Growth Inhibition %
Saline		Saline	0.98 $\pm$ 0.06	
Saline		$\text{E}_2^f$	1.71 $\pm$ 0.07	
Saline		13cRA <sup>a</sup>	0.99 $\pm$ 0.03	
13cRA <sup>a</sup>		$\text{E}_2^f$	1.70 $\pm$ 0.05	
AFP/Sal <sup>b</sup>		$\text{E}_2$	1.73 $\pm$ 0.07	
AFP/13cRA <sup>c</sup>		$\text{E}_2$	1.61 $\pm$ 0.07	14
AFP13cRA <sup>d</sup>		$\text{E}_2$	1.49 $\pm$ 0.10 <sup>g</sup>	30
AFP/13cRA <sup>e</sup>		$\text{E}_2$	1.52 $\pm$ 0.05	26

<sup>a</sup> 0.5  $\mu\text{g}$  13-cis-retinoic acid (13cRA) in 0.1 ml was injected i.p.

<sup>b</sup> 5  $\mu\text{g/ml}$  AFP was added to an equal volume of saline and incubated at room temperature for 1 h. 0.1 ml of this mixture was injected i.p. into each mouse.

<sup>c</sup> To 20  $\mu\text{g/ml}$  AFP in 1 ml was added 25  $\mu\text{l}$  of a 200  $\mu\text{g/ml}$  solution of 13cRA, and these were incubated together for 1 h at room temperature. 0.1 ml of this mixture was injected into each mouse.

<sup>d</sup> As in c, except AFP was at a concentration of 2.5  $\mu\text{g/ml}$ .

<sup>e</sup> As in c, except AFP was at a concentration of 0.25  $\mu\text{g/ml}$ .

<sup>f</sup> 0.5  $\mu\text{g}$   $\text{E}_2$  in 0.1 ml was injected i.p. to stimulate uterine growth.

<sup>g</sup> Significant inhibition,  $p < 0.05$ ; Wilcoxon Sum of Ranks Test.

Our colleagues at McGill University have run out of batch 18 ErhAFP. They have licensed the rights to their patent on their method of production and purification of ErhAFP to Atlantic Biopharmaceuticals, Inc. This company has invested in the materials needed to make large quantities of ErhAFP, and they are presently scaling up production of this protein in anticipation of clinical trials for use in certain autoimmune diseases (rheumatoid arthritis and myasthenia gravis), which is their interest, and in breast cancer if our results warrant an application in breast cancer. As this new material becomes available, we will continue testing its biological activity in our breast cancer assays according to the aims in this grant application. In the meantime, we have begun testing two sources of AFP produced at Albany Medical College. One is domain III of human AFP produced in a baculovirus expression system (BrhAFP), and the other is natural human AFP secreted by a human hepatoma grown in tissue culture (NhAFP).

*BrhAFP*. The gene for full-length human AFP was not commercially available. However, the cDNA for Domain III of human AFP was available and was obtained from the American Type Culture Collection. We decided to test Domain III of AFP for activity before trying to isolate the gene for the full-length molecule. As described below, we were quite fortunate in that Domain III contained all of the activity found in the full-length molecule. Prior to describing those results, let me take you through our method for production and purification of Domain III of human AFP.

The desired cDNA was amplified using PCR and subcloned into TA cloning vector (Invitrogen) in order to provide convenient "sticky" ends. This subcloning step permitted directional cloning of our cDNA into a baculovirus transfer vector downstream of a polyhedron promoter and flanked by viral sequences necessary for allelic replacement. Transfer vectors were modified to include a segment which codes for a polyHistidine region and a thrombin cleavage site on the N-terminus of each polypeptide.

Sf9 cells grown in 25 cm<sup>2</sup> flasks were cotransfected with 1 µg of BaculoGold linear viral DNA (Invitrogen, Inc.) containing a lethal mutation and with 2 µg of recombinant baculovirus transfer vector and incubated for 4 h in order to allow allelic replacement of the lethal mutation. After growing in complete medium for 4-6 days, media containing virus was harvested and stored at 4°C. Virus production was monitored by Western blot analysis (for AFP) and titered by plaque assay. Virus was amplified about 400 fold in each of two subsequent passages through Sf9 cells, in order to provide enough virus for large-scale production of protein. Sf9 cells were also used for the large-scale protein production. These cells were removed from the culture medium by centrifugation, and the non-secreted fusion protein (His-tagged AFP) was then solubilized and purified by passing the crude preparation over an affinity column to which the polyHis linker binds, allowing undesired proteins to pass through unretarded by the column. His-tagged AFP was then eluted from the column with imidazole, the linker was removed (by addition of thrombin, followed by dialysis), and AFP identity was confirmed by SDS-PAGE, Western blot, amino terminal protein sequencing, and amino acid analysis.

This material was tested for activability to antiestrogenic activity in the immature mouse uterus bioassay. As shown in Table 6, E<sub>2</sub>-transformed BrhAFP significantly inhibited E<sub>2</sub>-stimulated growth of immature mouse uterus. Untransformed BrhAFP was not inhibitory.

Table 6  
Inhibition of E<sub>2</sub>-Stimulated Mouse Uterine Growth  
by E<sub>2</sub>-Transformed BrhAFP

Injectant 1	1 hr	Injectant 2	Mean Uterine Weight ± SE (mg/g body wt)	Growth Inhibition %
Saline	→	Saline	0.82 ± 0.08	
Saline	→	E <sub>2</sub>	1.53 ± 0.05	
E <sub>2</sub>	→	E <sub>2</sub>	1.57 ± 0.08	
AFP/Sal <sup>a</sup>	→	E <sub>2</sub>	1.64 ± 0.11	
AFP/E <sub>2</sub> <sup>b</sup>	→	E <sub>2</sub>	1.36 ± 0.04 <sup>c</sup>	28

<sup>a</sup> 5 µg/ml of BrhAFP was mixed with an equal volume of saline for 1 h at room temperature, and 0.1 ml of this mixture was injected into the mice.

<sup>b</sup> 5 µg/ml of BrhAFP was mixed with an equal volume of 10 µg/ml E<sub>2</sub> for 1 h at room temperature, and 0.1 ml of this mixture was injected into the mice.

<sup>c</sup> Significant inhibition, p < 0.05, Wilcoxon Sum of Ranks Test.

Similarly, E<sub>2</sub>-transformed BrhAFP significantly inhibited E<sub>2</sub>-stimulated growth of human MCF-7 breast cancer cells into postconfluent foci, and as expected, untransformed BrhAFP was not inhibitory (Figure 8).




Fig. 8. Inhibition of growth of MCF-7 breast cancer cells in culture by tBrhAFP

**NhAFP.** Experiments were carried out to test our theory that E<sub>2</sub>-mediated activation of AFP can take place under physiological conditions in utero. In order to mimic those conditions, a human hepatoma (Hep G-2) which actively secretes AFP was grown in serum-free medium in the presence or absence of E<sub>2</sub> at a concentration of 10<sup>-9</sup> M. After 4 days of culture, supernatant was harvested and tested in the immature mouse uterus bioassay and the MCF-7 foci assay. As shown in Table 7, crude supernatant from hepatoma cells grown in 10<sup>-9</sup> M E<sub>2</sub> significantly inhibited E<sub>2</sub>-stimulated growth of mouse uterus, while supernatant from cells grown in the absence of E<sub>2</sub> was not inhibitory. The concentrations of AFP in these two supernatants were similar, suggesting that the presence of physiological levels of E<sub>2</sub> in the Hep G-2 growth medium uniquely resulted in the

formation of a growth-regulatory product. We believe this product is the antiestrogenic form of AFP, and we are carrying out the requisite experiments to substantiate this hypothesis.

Table 7  
**Inhibition of E<sub>2</sub>-Stimulated Mouse Uterine Growth  
 by the Culture Supernatant from Hep G-2 Human Hepatoma**

Injectant 1	1 hr →	Injectant 2	Mean Uterine Weight ± SE (mg/g body wt)	Growth Inhibition %
Saline		Saline	0.85 ± 0.04	
Growth Medium		Saline	0.91 ± 0.06	
Growth Medium with 10 <sup>-9</sup> M E <sub>2</sub>		Saline	0.98 ± 0.06	
Growth Medium		E <sub>2</sub>	1.53 ± 0.08	
Growth Medium with 10 <sup>-9</sup> M E <sub>2</sub>		E <sub>2</sub>	1.58 ± 0.06	
Culture Supernatant <sup>a</sup>		E <sub>2</sub>	1.66 ± 0.08	
Culture Supernatant <sup>b</sup> with 10 <sup>-9</sup> M E <sub>2</sub>		E <sub>2</sub>	1.35 ± 0.08 <sup>c</sup>	38

<sup>a</sup> This culture supernatant contained 68 µg/ml. 0.2 ml of this crude supernatant was injected i.p. into each mouse.

<sup>b</sup> This culture supernatant contained 56 µg/ml. 0.2 ml of this crude supernatant was injected i.p. into each mouse.

<sup>c</sup> Significant inhibition,  $p < 0.05$ , Wilcoxon Sum of Ranks Test.

No additional incubation with high concentrations of E<sub>2</sub> was required to achieve this inhibitory activity. This is important because the concentrations of E<sub>2</sub> in the supernatant are physiological and would be well tolerated in vivo. This may obviate our need to explore other activating ligands, a key component in the first aim of this proposal. These supernatants were also tested against MCF-7 cells growing in culture. Again, the supernatant from hepatoma cells growing in 10<sup>-9</sup> M E<sub>2</sub> was inhibitory and the other supernatant without E<sub>2</sub> was not (Figure 9).




Fig. 9. Inhibition of MCF-7 breast cancer cells in culture by NhAFP.

We have not yet proven that the activity in this supernatant is due to AFP, but these experiments are currently under way.

Work has begun determining receptor content of tumor lines that will be used in this study. Receptors for estrogen, progesterone and androgen have been determined. Receptors for AFP and IGF-1 will be determined during year 2. Assays were performed by radioligand binding assay as described in the manuals for RIANEN Assay Systems (NEN DuPont). Cytosols were prepared by homogenization of cell pellets of cell lines obtained from culture, followed by ultracentrifugation at 65,000xg for 1 hour. After analysis of cytosols for protein content (Biorad Systems), portions were combined with the appropriate tritium-labeled steroid hormone (with and without excess radioinert steroid inhibitor) and were incubated overnight at 4°C. After adsorption of unbound steroid with dextran-coated charcoal and clarification by low-speed centrifugation, their content of protein-bound tritium was determined by liquid scintillation counting. Receptor content for each tumor line was calculated from Scatchard plots of the data, and the results are shown below in Table 8.

Table 8  
**Estrogen, Progestin and Androgen Receptors in Tumor Cell Lines**

	<i>fmol/mg cytosol protein</i>		
	ER	PR	AR
MCF-7 (breast)	117	96	281
T47D (breast)	621	381	356
MDA (breast)	0	57	N.D.
HS578T (breast)	0	31	250
LNCaP (prostate)	309	106	600

N.D. Not determined due to insufficient quantity of cytosol protein

## Conclusions

a. ***Implications of Work.*** We have established that recombinant AFP can be transformed by incubation with sex steroid hormones or retinoids into an inhibitor of  $E_2$ -stimulated human breast cancer growth. This important milestone not only shows that recombinant material has anticancer activity similar to that of the natural material, but also gives credence that the requisite quantity of material for clinical trial can be achieved. In addition, it was found that the active site in AFP responsible for its antiestrogenic function is contained within the third domain of the AFP molecule. The fact that full activity is contained in the third domain of the molecule suggests that even smaller portions of the molecule may retain activity and lead to a more stable and perhaps synthetic product. Conversion to its antiestrogenic form is a rather labile property of both the recombinant and natural isolates of AFP. It is destroyed by harsh conditions of pH, temperature, exposure to chaotropic agents and exposure to denaturants. Therefore, conditions of production, purification and storage must be carefully controlled to preserve this property of the molecule.

We have also established that the active form of AFP can be produced in mammalian cell culture when a human liver cancer which secretes AFP is grown in the presence of physiological levels of  $E_2$ . This adds support to our hypothesis that the active form of AFP is produced in utero where the concentrations of AFP and  $E_2$  are very similar to those found in our culture medium. We speculate that the physiological basis for this product is to dampen the response of fetal tissues to sex steroid hormones which are prevalent during gestation. The epidemiological data showing a relationship between increased AFP and reduced breast cancer incidence can be explained by  $E_2$ -transformed AFP crossing the placenta, entering the maternal circulation and extinguishing premalignant foci in the breast that if left unabated would be promoted toward malignancy under the influence of estrogen.

b. ***Future Work.*** Our future work will continue to be directed toward isolating and capturing the active form of AFP so that it can be studied as a treatment for breast cancer. One of the first priorities in year 2 will be to chronically treat mice bearing the estrogen-dependent human MCF-7 breast cancer xenograft with one of our active forms of AFP and assess through histomorphometric studies the type of damage (lethal or non-lethal) done to the tumor. Also, the assays for AFP receptor and IGF<sub>1</sub> receptor will be developed, and these receptors will be quantitated in the tumors described in Table 8 on Page 19 of this report. We will then begin treating a variety of these tumors with the active form of AFP to determine their sensitivity to this agent and to assess whether their receptor status predicts their sensitivity to AFP. By the end of year 2 we will have a large supply of reliably active AFP that will be used to complete the remaining aims of our original grant proposal.

## References

1. Jacobson HI, Janerich DT. Pregnancy-altered breast cancer risk: mediated by maternal serum AFP? In: GJ Mizejewski, HI Jacobson (eds), *Biological Activities of Alpha-fetoprotein*, Vol 2. Boca Raton, FL: CRC Press, 1989:93-100.
2. Ekblom A, Trichopoulos D, Adami H, Hsieh C, Lan S. Evidence of prenatal influences on breast cancer risk. *Lancet* 1992; 340:1015-8.
3. Brock DJ, Sutcliffe RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. *Lancet* 1972; 2:197-9.
4. Kelsey JL, Hildreth NG. *Breast and Gynecologic Cancer Epidemiology*. Boca Raton, FL: CRC Press, 1983.
5. Crandall BF, Lebhey TB, Schrott PC, Matsumoto M. Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight. *Clin Chem* 1983; 29:531-3.
6. Gray GE, Henderson BE, Pike MC. Changing ratio of breast cancer incidence rates with age of black females compared with white females in the United States. *J Natl Cancer Inst* 1980; 64:461-3.
7. Pike MC, Spicer DV, Dahmouch L, Press MF. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. *Epidemiol Rev* 1993; 15:17-35.
8. Halmesmaki E, Autti I, Granstrom ML, Heikinheimo M, Raivio KO, Ylikorkala O. Alpha-fetoprotein, human placental lactogen, and pregnancy specific beta 1 glycoprotein in pregnant women who drink: relation to fetal alcohol syndrome. *Am J Obstet Gynecol* 1986; 155:598-602.
9. Howe G, Rohan T, Decarli A, Iscovich J, Kaldor J, Katsouyanni K, Marubini E, Miller A, Riboli E, Toniolo P, et al. The association between alcohol and breast cancer risk: evidence from the combined analysis of six dietary case control studies. *Int J Cancer* 1991; 47:707-10.
10. Clayton-Hopkins JA, Olsen PN, Blake AP. Maternal serum AFP levels in pregnancy complicated by hypertension. *Prenatal Diagnosis* 1982; 2:47-54.
11. Thompson WD, Jacobson HI, Negrini B, Janerich DT. Hypertension, pregnancy and risk of breast cancer. *J Natl Cancer Inst* 1989; 81:1571-4.
12. Wald N, Barker S, Peto R. Maternal serum  $\alpha$ -fetoprotein levels in multiple pregnancy. *Br. Med J* 1975; 1:651-2.
13. Jacobson HI, Thompson WD, Janerich DT. Multiple births and maternal risk of breast cancer. *Am J Epidemiol* 1989; 129:865-73.
14. Brock DJH, Sutcliffe RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. *Lancet* 1972; 2:197-8.
15. Janerich DT, Mayne ST, Thompson WD, Stark AD, Fitzgerald EF, Jacobson HI. Familial clustering of neural tube defects and gastric cancer. *Int J Epidemiol* 1990; 19:516-21.
16. Allen SHG, Bennett JA, Mizejewski GJ, Andersen TT, Ferraris S, Jacobson HI. Purification of alpha-fetoprotein from human cord serum with demonstration of its antiestrogenic activity. *Biochim Biophys Acta* 1993; 1202:135-42.
17. Jacobson H, Marotta D, Mizejewski GJ, Bennett J, Andersen T. Estradiol-induced changes in spectral and biological properties of alpha-fetoprotein. *Tumour Biol* 1990; 11:104.
18. Mizejewski GJ, Vonnegut M, Jacobson HI. Estradiol-activated  $\alpha$ -fetoprotein suppresses the uterotrophic response to estrogens. *Proc Natl Acad Sci USA* 1983; 80:2733-2737.
19. Evans RM. The steroid and thyroid hormone receptor superfamily. *Science* 1988; 240:889-95.
20. Jacobson HI, Bennett JA, Mizejewski GJ. Inhibition of estrogen-dependent breast cancer growth by a reaction product of  $\alpha$ -fetoprotein and estradiol. *Cancer Res* 1990; 50:415-420.
21. Crandall B. Alpha-fetoprotein: A review. In: *CRC Reviews in Clinical Laboratory Sciences*, 1981; 15:127-85. Boca Raton, FL: CRC Press.

22. Reyes FI, Boroditsky RS, Winter JSD, Faiman C. Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations. *J Clin Endocrinol Metab* 1974; 38:612-7.
23. Bennett JA, Mizejewski GJ, Allen SHG, Zhu SJ, Jacobson HI. Transformation of alpha-fetoprotein to a negative regulator of estrogen-dependent growth by ligands of the steroid/thyroid hormone receptor superfamily. *Proc Am Assoc Cancer Res* 1993; 34:1452.

### **Bibliography of Publications**

Bennett JA, Mizejewski GJ, Allen SHG, Zhu SJ, Jacobson HI. Transformation of alpha-fetoprotein to a negative regulator of estrogen-dependent growth by ligands of the steroid/thyroid hormone receptor superfamily. *Proc Am Assoc Cancer Res* 1993; 34:1452.

Bennett JA, Semeniuk DJ, Jacobson HI, Murgita RA. Inhibition of human breast cancer growth by recombinant human alpha-fetoprotein. *Proc Int Soc Oncodevel Biol Med* 1995; 23.

### **Personnel Receiving Pay**

James A. Bennett, Ph.D.	Principal Investigator
Herbert I. Jacobson, Ph.D.	Coinvestigator
Theresa Kellom, Ph.D.	Coinvestigator
ShuJi Zhu	Research Associate
Andrea Mirarchi	Research Technician